In a recent immunohistochemistry study (7), antibodies against Em2G11 have shown excellent properties for distinguishing between cystic and alveolar echinococcosis. Although reported to not cross-react with purified laminated layer fractions from in vitro–kept E. vogeli (10), antibodies against Em2G11 exhibited an unusual and possibly discriminatory staining pattern when applied to the E. vogeli lesion from the patient reported here. Antibodies against EM10, which has not before been used for species discrimination on tissue sections, have also shown different staining properties.

Our findings suggest that there may be more undiagnosed cases of polycystic neotropical echinococcoses in immigrants from South America. In retrospect, the treatment (although aimed at E. granulosus) was successful despite the polycystic and proliferative nature of E. vogeli lesions, as indicated by an uneventful prolonged follow-up period for this patient with a well-circumscribed liver lesion. If neotropical echinococcosis had been considered before surgery (on the basis of radiologic features and the patient’s origin), the management would also have included a preoperative and prolonged course of albendazole therapy.

Acknowledgments
We are grateful to Klaus Brehm and Matthias Frosch for providing the antibody against EM10 and to Peter Deplazes for providing the Em2G11 antibody against Em2.

T.F.B. was supported by German Research Foundation grant no. DFG KE 282.

Reference
1. D’Alessandro A, Rausch RL. New aspects of neotropical polycystic (Echinococcus vogeli) and unicityc (Echinococcus oligarthrus) echinococcosis. Clin Microbiol Rev. 2008;21:380–401. http://dx.doi.org/10.1128/CMR.00050-07
2. Tappe D, Stich A, Frosch M. Emergence of polycystic neotropical echinococcosis. Emerg Infect Dis. 2008;14:292–7. http://dx.doi.org/10.3201/eid1402.070742
3. Knapp J, Chirica M, Simonnet C, Grenouillet F, Bart JM, Sako Y, et al. Echinococcus vogeli infection in a hunter, French Guiana. Emerg Infect Dis. 2009;15:2029–31. http://dx.doi.org/10.3201/eid1512.eid1512.090940
4. Stijnis C, Bart A, Brosens L, Van Gool T, Grobusch M, et al. First case of Echinococcus vogeli infection imported to the Netherlands, January 2013. Euro Surveill. 2013;18:20448.
5. Bowles J, Blair D, McManus DP. Genetic variants within the genus Echinococcus identified by mitochondrial DNA sequencing. Mol Biochem Parasitol. 1992;54:165–73. http://dx.doi.org/10.1016/0166-6851(92)90109-W
6. Deplazes P, Gottstein B. A monoclonal antibody against Echinococcus multilocularis Em2 antigen. Parasitol. 1991;103:41–9. http://dx.doi.org/10.1017/S0031182000059278
7. Barth TF, Herrmann TS, Tappe D, Stark L, Gruner B, Buttenschøen K, et al. Specific and sensitive immunohistochemical diagnosis of human alveolar echinococcosis with the monoclonal antibody Em2G11. PLoS Negl Trop Dis. 2012;6:e1877.
8. Helbig M, Frosch P, Kern P, Frosch M. Serological differentiation between cystic and alveolar echinococcosis by use of recombinant larval antigens. J Clin Microbiol. 1993;31:3211–5.
9. Oostburg BF, Vrede MA, Bergen AE. The occurrence of polycystic echinococcosis in Suriname. Ann Trop Med Parasitol. 2000;94:247–52. http://dx.doi.org/10.1080/0001706X(00)0006429
10. Hemphill A, Stettler M, Walker M, Siles-Lucas M, Fink R, Gottstein B. In vitro culture of Echinococcus multilocularis and Echinococcus vogeli metacestodes: studies on the host–parasite interface. Acta Trop. 2003;85:145–55. http://dx.doi.org/10.1016/S0001-706X(02)00220-6

Address for correspondence: Kees Stijnis, Academic Medical Center, Meibergdreef 9, Postbus 22660, 1100 DD Amsterdam, the Netherlands; email: c.stijnis@amc.nl

Post-Chikungunya Rheumatoid Arthritis, Saint Martin

Maud Foissac, Emilie Javelle, Simon Ray, Bruno Guérin, Fabrice Simon

Author affiliations: Hospital Jacques Puel, Rodez, France (M. Foissac, S. Ray, B. Guérin); Laveran Military Teaching Hospital, Marseille, France (E. Javelle, F. Simon)

DOI: http://dx.doi.org/10.3201/eid2103.141397

To the Editor: In October 2013, autochthonous transmission of chikungunya was detected in the Caribbean area, which resulted in the current epidemic of chikungunya in the Western Hemisphere (1). The chikungunya virus strain that caused this epidemic belongs to the Asian lineage, not to the strain descending from the East/Central/South African (ECSA) lineage that spread in the Indian Ocean region after 2004. This ECSA lineage was reported mainly to cause long-lasting musculoskeletal and rheumatic disorders in chikungunya virus–infected patients (2–8). In 1984 in South Africa, Brighton and Simson reported post-chikungunya destructive polyarthritis (6). Twenty years later, the arthritogenic pathogenesis of viruses in the ECSA chikungunya virus lineage was confirmed after outbreaks in the Indian Ocean region (2–5,7,8).

Because >870,000 suspected cases of chikungunya have occurred during the past 12 months in the Western Hemisphere (http://www.paho.org/hq/index.php?option=com_content&view=article&id=9436), it is crucial to know whether infection with the epidemic Asian lineage was responsible for the occurrence of post-chikungunya rheumatoid arthritis (2–8).
A 70-year-old woman (artist–painter) in Saint Martin sought treatment in June 2014 for joint pains and disabilities persisting after chikungunya. Her medical history included high blood pressure, hypothyroidism, and 3 dengue infections. During October 2013, the patient had high-grade fever, intense fatigue, and a maculopapular truncular exanthema without lymphadenopathy. Five days later, she had distal polyarthritis (joint pain and swelling) in interphalangeal joints, wrists, and ankles without plantar involvement. Recent infection with chikungunya virus was confirmed (IgM and IgG against chikungunya virus was detected in 2 blood samples), and recent dengue was excluded according to the criteria of the National Reference Center on Arboviral Diseases (http://www.niaid.nih.gov/labsandresources/resources/dmid/wrceva/Pages/default.aspx).

Despite initial brief improvement, the patient never totally recovered and subsequently chronic polyarthritis developed, which involved >10 joints, including interphalangeal joints, wrists, and knees. Nonsteroidal antiinflammatory drugs did not relieve the diffuse pain, stiffness, and swelling. She was given oral corticotherapy (20 mg/day) beginning in January 2014. She was referred to another hospital in France 5 months later because of treatment failure. She reported continuous pain in the left knee and wrists and multiple tenosynovitis on flexors and extensors of the fingers (Figure). She did not report any fever or axial, shoulder, or hip pain. Radiographs of the involved joints showed no abnormalities.

The patient had mild inflammation (C-reactive protein level 13 mg/L, fibrinogen level 3.4 g/L) but no specific autoimmunity (results were negative for anticitrullinated peptide antibodies, rheumatoid factor, antineutrophil cytoplasmic antibodies, and antinuclear antibodies). Serologic results for viruses other than chikungunya virus were negative or indicated past vaccination. The patient’s condition met the 2010 American College of Rheumatology/European League against Rheumatism criteria for rheumatoid arthritis (https://www.rheumatology.org/practice/clinical/classification/ra/ra_2010.asp), and the only cause observed for this disease was acute chikungunya. For this corticosteroid-resistant, seronegative, and nondestructive post-chikungunya rheumatoid arthritis, methotrexate was prescribed at a weekly low dose after exclusion of contraindications, but the patient was not followed-up after she returned to Saint Martin.

The reported case was caused by chikungunya virus infection during an epidemic in Saint Martin in October 2013. This unfavorable post-chikungunya outcome of chronic inflammatory rheumatism 8 months later indicates a probable course of post-chikungunya disorders in the Western Hemisphere, as has already been observed in Africa and Asia. Previous outbreaks in Réunion and India offer insights regarding patients’ post-chikungunya chronic status with long-lasting pain and disability, impaired quality of life, and extensive treatment (2,3,9).

The spectrum of post-chikungunya rheumatic and musculoskeletal disorders includes multiple tendinitis and tenosynovitis, plantar fasciitis, mechanical disbalance in susceptible joints, tunnel syndromes, edematous polyarthralgia, rheumatoid arthritis, and psoriatic arthritis (2,4,5). Although the proportion of patients with chronic disease has decreased, post-chikungunya chronic inflammatory rheumatism, mostly rheumatoid arthritis, develops in ≈5% of these patients (8). These patients had a poor prognosis and were given disease-modifying anti-rheumatic drugs (DMARDs), despite the postinfectious origin of rheumatism (4,5). Patients with post-chikungunya rheumatoid arthritis should benefit from methotrexate, which is recommended for treatment of classic rheumatoid arthritis (10).

In our experience, resistance to or dependence on corticosteroids beyond the third month after disease onset is highly evocative of post-chikungunya chronic inflammatory rheumatism. This finding requires early treatment with DMARDs to control the inflammatory process, prevent bone erosions, and prevent inevitable side effects of prolonged corticotherapy. To date, the efficacy of different DMARDs for treatment of post-chikungunya chronic inflammatory rheumatism has not been evaluated. Therefore, physicians should follow the international guidelines for treatment of classic rheumatoid arthritis and psoriatic polyarthritis, which recommend methotrexate as first-line treatment for patients fulfilling chronic inflammatory rheumatism criteria after 3 months of evolution.

We found that the Asian strain of chikungunya virus has induced arthritic disorders in the Western Hemisphere. Thus, a possible increase in post-chikungunya rheumatoid arthritis should not be overlooked. Physicians and public health authorities should prepare a response to the patients’
post-chikungunya stage in the epidemic areas. Clinical vigilance is recommended to identify patients with unfavorable outcomes 3 months after disease onset and for those in whom post-chikungunya chronic inflammatory rheumatism develops and who require specific treatment. Detailed guidelines for diagnosis and treatment of these patients with chronic rheumatoid arthritis are needed.

References

1. Nasci RS. Movement of chikungunya virus into the Western Hemisphere. Emerg Infect Dis. 2014;20:1394–5. http://dx.doi.org/10.3201/eid2008.140333

2. Mathew AJ, Goyal V, George E, Thekkemuriyil DV, Jayakumar B, Chopra A, et al. Rheumatic-musculoskeletal pain and disorders in a naive group of individuals 15 months following a chikungunya viral epidemic in south India: a population based observational study. Int J Clin Pract. 2011;65:1306–12. http://dx.doi.org/10.1111/j.1742-1241.2011.02792.x

3. Chopra A, Anuradha V, Ghorpade R, Saluja M. Acute chikungunya and persistent musculoskeletal pain following the 2006 Indian epidemic: a 2-year prospective rural community study. Epidemiol Infect. 2012;140:842–50. http://dx.doi.org/10.1017/S0950268811001300

4. Ribéra A, Degasne I, Jaffar Bandjee MC, Gasque P. Chronic rheumatic manifestations following chikungunya virus infection: clinical description and therapeutic considerations [in French]. Med Trop (Mars). 2012;72:83–5.

5. Bouquillard E, Combe B. A report of 21 cases of rheumatoid arthritis following chikungunya fever. A mean follow-up of two years. Joint Bone Spine. 2009;76:654–7. http://dx.doi.org/10.1016/j.jbspin.2009.08.005

6. Brighton SW, Simson IW. A destructive arthropathy following chikungunya virus arthritis: a possible association. Clin Rheumatol. 1984;3:253–8. http://dx.doi.org/10.1007/BF02030766

7. Ganu MA, Ganu AS. Post-chikungunya chronic arthritis—our experience with DMARDs over two year following. J Assoc Physicians India. 2011;59:83–6.

8. Essackjee K, Goorah S, Ramchurn SK, Cheeneebash J, Walker-Bone K. Prevalence of and risk factors for chronic arthralgia and rheumatoid-like polyarthritis more than 2 years after infection with chikungunya virus. Postgrad Med J. 2013;89:440–7. http://dx.doi.org/10.1136/postgradmedj-2012-131477

9. Marimoutou C, Vivier E, Olivier M, Boutin J-P, Simon F. Morbidity with chronic rheumatoid arthritis are needed. Detailed guidelines for diagnosis and treatment of these patients with chronic rheumatoid arthritis are needed.

10. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84. http://dx.doi.org/10.1002/art.23721

Address for correspondence: Maud Foissac, Maladies Infectieuses et Tropicales, Hôpital Jacques Puel, Ave de l’Hôpital 12027, Rodez CEDEX 9, France; email: maudpikmin@yahoo.fr

Molecular Detection of Ehrlichia chaffeensis in Humans, Costa Rica

Norman Rojas, Daniela Castillo, Priscilla Marin

Author affiliation: Universidad de Costa Rica, San Jose, Costa Rica

DOI: http://dx.doi.org/10.3201/eid2103.131759

To the Editor: Human monocytic ehrlichiosis (HME), a tickborne zoonosis caused by the rickettsial pathogen Ehrlichia chaffeensis (Rickettsiales: Anaplasmataceae), is considered an emerging pathogen in the United States and, increasingly, in many countries around the world (1). In Costa Rica, past reports of human cases of ehrlichiosis were diagnosed solely by clinical evaluation and cytomorphology (2,3); recent studies have detected E. canis in dogs and their ectoparasites (4,5). However, molecular detection of natural Ehrlichia infection detected in humans in Costa Rica has not been reported.

In a small rural area of Zarcero, province of Alajuela, north central region of Costa Rica, blood samples were drawn from 20 patients who had histories of tick bites and nonspecific symptoms of fatigue, arthralgia, and myalgia beginning ≥1 year before sampling. The samples were referred for Ehrlichia molecular analysis. In addition, blood samples were drawn from 2 patients of 2 health care clinics in the Alajuela province districts of San Carlos and Alajuela who had clinical signs compatible with recent ehrlichiosis; the samples were sent for confirmation by PCR. All anticoagulated samples were transported within 4 hours to the laboratory for processing. No serologic assays were performed; cytomorphologic estimation and laboratory data were provided from the local health facilities, mostly generated 1 year before this molecular analysis.

DNA was isolated the same day of sampling from whole blood (200 μL) by using the QIAamp Blood Kit (QIAGEN, Santa Clarita, CA, USA) according to the manufacturer’s instructions. Purified DNA from each blood sample was quantified by spectrophotometry, yielding 20–32 ng/μL of DNA. Nested PCR assays were performed as described (6,7). To avoid DNA contamination, first PCR, second PCR, and electrophoresis were performed in separate rooms, following strict rules of pipetting and cleaning, and repeated ≥3 times. In addition, endpoint PCR for the variable-length PCR target gene was performed on samples that were positive in the nested assay, according to Paddock et al. (8). For DNA sequencing, PCR reactions were performed, and products were separated by agarose gel electrophoresis. A nested PCR mixture containing water and 1 containing unrelated Brucella abortus DNA were used as negative controls in every assay. As an internal